الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
Hepatitis B Virus (HBV) infection remains a major global
public health problem, despite the availability of a highly effective
vaccine and improvements in antiviral therapy. Globally, of the two
billion people previously infected, more than 350 million people
have developed chronic HBV infection, causing one million HBVrelated
deaths each year. HBV infection varies according to
geography, with chronic HBV prevalence ranging from0.2% to 20%.
Approximately 45% of the world’s population lives in highly
endemic areas, such as Africa and the Asia-Pacific region excluding
Japan, Australia and New Zealand.
Hepatitis C Virus (HCV) is a major cause of liver disease
worldwide and a potential cause of substantial morbidity and
mortality in the future. The complexity and uncertainty related to the
geographic distribution of HCV infection and chronic hepatitis C,
determination of its associated risk factors, and evaluation of
cofactors that accelerate its progression, underscore the difficulties
in global prevention and control of HCV.
The aim of this study is to determine the prevalence of Hepatitis
B virus surface Antigen (HBsAg) and Hepatitis C Virus Antibodies
(HCV Abs) among workers of Zagazig Faculty of medicine and its
hospitals and determination of the possible risk factors for
prevalence of these health problems.